Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in HFNEF
NCT02354573Completed
- Sponsor
- University of Oxford
- Start
- Dec 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ivabradine in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by University of Oxford. Primary endpoint: Change in Peak Oxygen Consumption at 2 weeks. Started Dec 2011; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02354573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354573.